CUMYL-3TMS-PRINACA

CUMYL-3TMS-PRINACA
Identifiers
  • N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide
Chemical and physical data
FormulaC23H31N3OSi
Molar mass393.606 g·mol−1
3D model (JSmol)
  • C[Si](C)(C)CCCn1nc(C(=O)NC(C)(C)c2ccccc2)c2ccccc12
  • InChI=1S/C23H31N3OSi/c1-23(2,18-12-7-6-8-13-18)24-22(27)21-19-14-9-10-15-20(19)26(25-21)16-11-17-28(3,4)5/h6-10,12-15H,11,16-17H2,1-5H3,(H,24,27)
  • Key:BFLYAEBVCZMSPK-UHFFFAOYSA-N

CUMYL-3TMS-PRINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. Along with the related compound ADMB-3TMS-PRINACA that was reported several months earlier, CUMYL-3TMS-PRINACA is one of the only psychoactive drugs ever reported that contains a silicon atom.[1] Another example of a silicon-containing drug is sila-haloperidol.[2]

  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
  2. ^ "Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate". 2008.